Specialist allergy advice allows vaccination in patients with reactions to COVID‐19 vaccines

Harper, Verah; Gurugama, Padmalal; Ewan, PW; Nasser, S.; Sellaturay, Priya

doi:10.1111/cea.14069

Cited by 2 publications

(2 citation statements)

References 10 publications

(20 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Increasing evidence shows that non‐IgE‐mediated mechanisms, e.g., IgG‐mediated anaphylaxis and complement activation‐related pseudoallergy (CARPA), may be involved in some of these cases who develop anaphylaxis reactions, 24 limiting the role of skin tests and other in vitro diagnostic tests 25 . Some patients with previous immediate reactions to mRNA vaccinations are able to tolerate subsequent doses without recurrence of a similar reaction 3 following specialist allergy evaluation and risk stratification 26 . Finally, some of these reactions may have been immunization stress‐related responses (ISRRs) due to vaccination‐related psychologic reactions which occur due to anxiety or stress mimicking acute allergic reactions.…”

Section: Discussionmentioning

confidence: 99%

“…25 Some patients with previous immediate reactions to mRNA vaccinations are able to tolerate subsequent doses without recurrence of a similar reaction 3 following specialist allergy evaluation and risk stratification. 26 Finally, some of these reactions may have been immunization stress-related responses (ISRRs) due to vaccination-related psychologic reactions which occur due to anxiety or stress mimicking acute allergic reactions.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Asia Pacific perspectives on the second year of the COVID‐19 pandemic: A follow‐up survey

Pawankar

Thong

Tiongco‐Recto

et al. 2022

Clin Experimental Allergy

View full text Add to dashboard Cite

BackgroundThe Coronavirus disease 2019 (COVID‐19) pandemic is currently in its third year. This follow‐up survey was commissioned by the Asia Pacific Association of Allergy Asthma and Clinical Immunology (APAAACI) Task Force on COVID‐19 to compare and contrast changes in the epidemiology, clinical profile, therapeutics and public health measures of the pandemic in the Asia Pacific region.MethodsA questionnaire‐based survey comprising 32 questions was electronically sent out to all 15 member countries of APAAACI using Survey Monkey® from 1 December 2021 to 28 February 2022.ResultsSeventeen responses were received from 14/15 (93.4%) member countries and 3 individual members. Mild‐to‐moderate COVID‐19 predominated over severe infection, largely contributed by COVID‐19 vaccination programmes in the region. The incidence of vaccine adverse reactions in particular anaphylaxis from messenger ribonucleic acid (mRNA) vaccines was no longer as high as initially anticipated, although perimyocarditis remains a concern in younger males. Novel therapeutics for mild‐to‐moderate disease including neutralizing antibodies casirivimab/imdevimab (REGEN‐COV®) and sotrovimab (Xevudy®), anti‐virals Paxlovid® (nirmatrelvir and ritonavir) and Molnupiravir pre‐exposure prophylaxis for high‐risk persons with Tixagevimab and Cilgavimab (Evusheld) are now also available to complement established therapeutics (e.g., remdesivir, dexamethasone and baricitinib) for severe disease. In the transition to endemicity, public health measures are also evolving away from containment/elimination strategies.ConclusionsWith access to internationally recommended standards of care including public health preventive measures, therapeutics and vaccines among most APAAACI member countries, much progress has been made over the 2‐year period in minimizing the morbidity and mortality from COVID‐19 disease.

show abstract